From thestreet.com......https://www.thestreet.com/s/alzheimers-drug-stocks-may-be-worth-wait/newsanalysis/biotech/10383640.html?puc=_tscs
Check out the section on Transition Therapeutics;
Transition Therapeutics (TTHI - Cramer's Take - Stockpickr):
A recent development partnership with Elan has helped raise the visibility of Transition and its drug ELND-005. Unfortunately, it will be a while before we see new clinical data. A phase II study is expected to begin at the end of the year or early in the first quarter 2008. With an 18-month dosing period, data won't be available until 2009.
Unfortunately as with many other analysts, no one mentions the Diabetes programs that they currently have or the clinical trial results from them. There is no pending clinial trial data out there as you'd expect that a trial bombed the way this stock has been acting lately.
With the increased volume we have been seeing (kind of interesting that it happened right after the ThinkEquity conference in New York) this will probably end up present itself as a great buying op for longs.
Although who knows how far this might get taken down. Once all the histeria settles, I expect a nice rebound but suggest everyone does their own DD and risk management.
I personally called the company regarding this recent SP volatility and asked questions, some of which involved Norvo and the implications if they opt out of the current arrangement.
Unless someones pulling wool over my eyes I'm going to ride this out and buy more at these low levels.
Were almost back at the range before the ELN deal was constructed.... unreal.